IP Verse

Pharmaceutical Formulations Comprising 4-{(1R)-2- [(6-{2-[(2,6-Dichlorobenzyl)Oxy] Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2- (Hydroxymethyl)Phenol - EP2400950

The patent EP2400950 was granted to Glaxo Group on May 22, 2019. The application was originally filed on Feb 26, 2009 under application number EP09779096A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2400950

GLAXO GROUP
Application Number
EP09779096A
Filing Date
Feb 26, 2009
Status
Granted And Under Opposition
Apr 19, 2019
Grant Date
May 22, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZFeb 24, 2020MAIWALDADMISSIBLE
HGFFeb 21, 2020HGFADMISSIBLE
NEDERLANDSCH OCTROOIBUREAUFeb 21, 2020NEDERLANDSCH OCTROOIBUREAUADMISSIBLE
TEVA PHARMACEUTICALSFeb 21, 2020ELKINGTON AND FIFEADMISSIBLE
AERAFeb 20, 2020AERAADMISSIBLE
AERAFeb 20, 2020BARDEHLE PAGENBERG SLADMISSIBLE
GILL JENNINGS & EVERYFeb 20, 2020GILL JENNINGS & EVERYADMISSIBLE
DEHNSFeb 18, 2020DEHNSADMISSIBLE
ARVEN ILAC SANAYI VE TICARETFeb 14, 2020SOYLUADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONUS2008003290
EXAMINATIONWO2007117911
INTERNATIONAL-SEARCH-REPORTUS2006239932
OPPOSITIONUS2006239932
OPPOSITIONUS2008003290
OPPOSITIONUS7439393
OPPOSITIONWO0028979
OPPOSITIONWO03024439
OPPOSITIONWO2005004845
OPPOSITIONWO2006008173
OPPOSITIONWO2006108572
OPPOSITIONWO2006124556
OPPOSITIONWO2007117911
OPPOSITIONWO2007135024
OPPOSITIONWO2008049842
SEARCHUS2006239932

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- NICOLA A. HANANIA ET AL, "The Efficacy and Safety of the Novel Long-Acting beta2 Agonist Vilanterol in Patients With COPD - A Randomized Placebo-Controlled Trial", CHEST, (20120701), vol. 142, no. 1, doi:10.1378/chest.11-2231, pages 119 - 127, XP055214172
OPPOSITION- 29th, General, Assembly, Tokyo, Japan, "WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects", 53rd WMA General AssemblyNote of Clarification on Paragraph 30 added) 59th WMA General Assembly, 53rd WMA General AssemblyNote of Clarification on Paragraph 30 added) 59th WMA General Assembly, URL: https://icgc.org/files/daco/WMA_Helsinki_2008_en.pdf, (20200420), XP055687498-
OPPOSITION- Anonymous, "A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)", US National Library of Medicine Clinicaltrails.gov, Clinicaltrials, pages 1 - 14, US National Library of Medicine Clinicaltrails.gov, URL: https://clinicaltrials.gov/ct2/show/record/NCT00606684?draw=2, (20200420), XP055687488-
OPPOSITION- Anonymous, "Dose Response Information to Support Drug Registration, CPMP/ICH/378/95", EMEA, pages 1 - 10, EMEA, (20181120), XP055525263-
OPPOSITION- Anonymous, "Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma full report 2007", Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma full report 2007, national heart, lung and blood institute, (20070101), pages 1 - 72, XP055687517-
OPPOSITION- Anonymous, "Theravance, Inc. Announces Positive Results of Clinical Program in Beyond Advair Collaboration", Biospace, pages 1 - 5, Biospace, URL: https://www.biospace.com/article/releases/theravance-inc-announces-positive-results-of-clinical-program-in-beyond-advair-collaboration-/, (20200420), XP055687523-
OPPOSITION- Anonymus, "GlaxoSmithKline and Theravance, Inc. Announce Positive Phase 2b Results For Once-Daily Fluticasone Furoate In The Treatment Of Asthma", (20200513), XP055694873-
OPPOSITION- C Myers, "GSK and Teravance announce positive phase 2b results for LABA, '444 in the Horizon Asthma Development Programme", URL: https://www.biospace.com/article/releases/glaxosmithkline-and-theravance-inc- announce-positive-phase-2b-results-for-once-daily-fluticasone-furoate-in-the- treatment-of-asthma-/?s=114, (20200513), XP055694882-
OPPOSITION- Fda, "Draft Guidance for Industry on Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment; Availability", Federal Register, (20071109), vol. 72, no. 2, page 63618, XP093166751-
OPPOSITION- Fda, "Guidance for Industry Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment ", DRAFT GUIDANCE, U.S. Department of Health and Human Services, (20071101), DRAFT GUIDANCE, XP093166733-
OPPOSITION- K. P. Gibbs, "25. Asthma", Clinical Pharmacy and Therapeutics. 4th ed., Livingstone Churchill, (20070101), pages 367 - 385, XP093166754-
OPPOSITION- W. • Hildebrand, "8 Klinische Prüfung von Arzneimitteln", Lehrbuch der Klinischen Pharmazie, Stuttgart, Wissenschaftliche Verlagsgesellschaft, (19980101), pages 103 - 114, XP093166739-
OPPOSITION- Olof Selroos, "Formoterol Turbuhaler® 4.5μg (Delivered Dose) has a Rapid Onset and 12-h Duration of Bronchodilation", Pulmornary Pharmacology & Therapeutics, Academic Press, GB, GB , (20020501), vol. 15, no. 2, doi:10.1006/pupt.2001.0335, ISSN 1094-5539, pages 175 - 183, XP093166727
OPPOSITION- M Cazzola, M G Matera, "Novel long-acting bronchodilators for COPD and asthma", British Journal of Pharmacology, Nature Pub. Group, etc., (20081001), vol. 155, no. 3, doi:10.1038/bjp.2008.284, ISSN 00071188, pages 291 - 299, XP055104106
OPPOSITION- Petr Pohunek, "Dose‐related efficacy and safety of formoterol (Oxis ® ) Turbuhaler ® compared with salmeterol Diskhaler ® in children with asthma", Pediatric Allergy and Immunology, Wiley-Blackwell Publishing Ltd., GB, GB , (20040201), vol. 15, no. 1, doi:10.1046/j.0905-6157.2003.00096.x, ISSN 0905-6157, pages 32 - 39, XP093166741
OPPOSITION- NEWMAN et al., "Evolution of dry powder inhaler design, formulation, and performance", respiratory MEDICINE, (200205), vol. 96, no. 05, pages 293 - 304, XP055695240
OPPOSITION- Donohue, "Minimal Clinically Important Differences in COPD Lung Function", COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 2, 2005 - Issue 1, vol. 2, no. 1, (2009-08-24), pages 111 - 124, URL: https://www.tandfonline.com/doi/abs/10.1081/COPD-200053377?journalCode=icop20, XP055687530
OPPOSITION- H. CHRYSTYN, "The Diskus™: a review of its position among dry powder inhaler devices", International Journal of Clinical Practice, (20070601), vol. 61, no. 6, pages 1022 - 1036, XP055253686
OPPOSITION- HANANIA et al., "The Efficacy and Safety of the Novel Long-Acting beta2 Agonist Vilanterol in Patients With COPD - A Randomized Placebo-Controlled Trial", Chest, (20120700), vol. 142, no. 1, pages 119 - 127, XP055214172
OPPOSITION- HANANIA et al., "The Efficacy and Safety of the Novel Long-Acting beta2 Agonist Vilanterol in Patients With COPO", CHEST, (20120700), vol. 142, no. 1, doi:10.1378/chest.11-2231, XP055214172
OPPOSITION- Nicola A. Hanania, Et Al, "The Efficacy and Safety of the Novel Long-Acting beta2 Agonist Vilanterol in Patients With COPD - A Randomized Placebo-Controlled Trial", CHEST, (20120701), vol. 142, no. 1, doi:10.1378/chest.11-2231, pages 119 - 127, XP055214172

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents